Gilead Sciences, Inc. (GILD) Expected to Post Earnings of $1.70 Per Share
Brokerages expect that Gilead Sciences, Inc. (NASDAQ:GILD) will report $1.70 earnings per share for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Gilead Sciences’ earnings. The highest EPS estimate is $2.11 and the lowest is $1.29. Gilead Sciences reported earnings per share of $2.70 during the same quarter last year, which indicates a negative year over year growth rate of 37%. The business is scheduled to report its next earnings report on Tuesday, February 6th.
On average, analysts expect that Gilead Sciences will report full year earnings of $8.72 per share for the current year, with EPS estimates ranging from $8.36 to $9.17. For the next fiscal year, analysts anticipate that the business will report earnings of $6.90 per share, with EPS estimates ranging from $6.03 to $8.04. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the prior year, the firm posted $2.75 EPS. The business’s revenue for the quarter was down 13.2% on a year-over-year basis.
Shares of Gilead Sciences (NASDAQ:GILD) traded up $0.21 during midday trading on Wednesday, hitting $76.09. 9,281,600 shares of the company’s stock were exchanged, compared to its average volume of 9,197,704. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27. The company has a market capitalization of $99,119.69, a P/E ratio of 7.92, a PEG ratio of -1.27 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.73%. Gilead Sciences’s dividend payout ratio is presently 23.69%.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the transaction, the executive vice president now owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 494,999 shares of company stock worth $37,404,139. 1.30% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in GILD. BlackRock Inc. boosted its stake in shares of Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after acquiring an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. increased its holdings in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Gilead Sciences by 1.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after purchasing an additional 310,607 shares in the last quarter. FMR LLC increased its holdings in Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares in the last quarter. Hedge funds and other institutional investors own 76.23% of the company’s stock.
WARNING: “Gilead Sciences, Inc. (GILD) Expected to Post Earnings of $1.70 Per Share” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-expected-to-post-earnings-of-1-70-per-share-2/1761989.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.